Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at Bank of America

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective decreased by Bank of America from $14.00 to $12.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price target points to a potential upside of 158.90% from the company’s previous close.

Several other analysts have also issued reports on YMAB. Morgan Stanley reduced their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Stock Down 6.6 %

YMAB traded down $0.33 during trading on Wednesday, reaching $4.64. The company’s stock had a trading volume of 195,646 shares, compared to its average volume of 467,754. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $18.19. The company has a market cap of $207.60 million, a price-to-earnings ratio of -8.58 and a beta of 0.65. The firm has a fifty day simple moving average of $6.46 and a two-hundred day simple moving average of $10.62.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period last year, the company earned ($0.02) EPS. As a group, equities analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in YMAB. State Street Corp increased its position in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Barclays PLC lifted its stake in Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after acquiring an additional 47,846 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $133,000. Finally, Caligan Partners LP grew its position in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.